<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":8638,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Bartlett v. Mut. Pharm. Co., 678 F.3d 30 (1st Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/e2ce47aedc09393b1f207adc43ffc06c'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/e2ce47aedc09393b1f207adc43ffc06c'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1HKRIC003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HKRIC003">Previous Result: <span>Ka Cheung v. Holder, 678 F.3d 66 (1st Ci...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1HKT1O003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HKT1O003">Next Result: <span>United States v. Jeanty, 467 Fed. Appx. ...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation negative" title="Negative"></div>
<div class='title left' title='Bartlett v. Mut. Pharm. Co., 678 F.3d 30 (1st Cir. 2012), Court Opinion'>
Bartlett v. Mut. Pharm. Co., 678 F.3d 30 (1st Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Bartlett v. Mut. Pharm. Co., 678 F.3d 30 (1st Cir. 2012), Court Opinion</div>
<div class='docId'>X1HKRI6003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Bartlett v. Mut. Pharm. Co.</div>
<div class='displayCitation'>2012 BL 107526</div>
<div class='displayCitation'>678 F.3d 30</div>
<div class='displayCitation'>bna a0d1u7v8x1</div>
<div class='displayCitation'>bna a0d1w0x2e2</div>
<div class='displayCitation'>bna a0d2f9q0m7</div>
<div class='displayCitation'>wkf1case:26031907</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HKRI6003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Bartlett v. Mut. Pharm. Co., 678 F.3d 30 (1st Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Bartlett v. Mut. Pharm. Co." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1HKRI6003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HKRI6003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HKRI6003" /><input id="title" name="title" type="hidden" value="Bartlett v. Mut. Pharm. Co., 678 F.3d 30 (1st Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="NEGATIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="e2ce47aedc09393b1f207adc43ffc06c" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HKRI6003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Fe%32ce%34%37aedc%30%39%33%39%33b%31f%32%30%37adc%34%33ffc%30%36c%2Fdocument%2FX%31HKRI%36%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/bcite/X1HKRI6003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/bcite/X1HKRI6003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/bcite/X1HKRI6003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/related_content/X1HKRI6003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1706027057155";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">678 F.3d 30</div>
<div class="cite" data-cite-type="DocketNumber">10-2277</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 107526</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, First Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
Karen L. BARTLETT, Plaintiff, Appellee, Gregory S. Bartlett, Plaintiff, v.
MUTUAL PHARMACEUTICAL COMPANY, INC., Defendant, Appellant, United Research
Laboratories, Inc., n/k/a URL Pharma, Inc.; Brooks Pharmacy, Defendants.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 10-2277.
</center></p>
<p><center>
Heard December 7, 2011. Decided May 2, 2012.
</center></p>
<div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of New
Hampshire, Joseph N. Laplante, J.
<span CLASS="page_no" data-cite="678 f 3d 31" data-cite-type="PrimaryFederalReporter" data-cite-pageno="31" data-primary-citation="678 F.3d 30">[*31]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="678 f 3d 32" data-cite-type="PrimaryFederalReporter" data-cite-pageno="32" data-primary-citation="678 F.3d 30">[*32]</span> </p></div>
<div id="para2" printdualcolumn="true"><p>

[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="678 f 3d 33" data-cite-type="PrimaryFederalReporter" data-cite-pageno="33" data-primary-citation="678 F.3d 30">[*33]</span> </p></div>
<div id="para2" printdualcolumn="true"><p>
Joseph P. Thomas with whom Linda E. Maichl, Paul J. Cosgrove, Ulmer &amp; Berne
LLP, Stephen J. Judge, Pierre A. Chabot and Wadleigh, Starr &amp; Peters PLLC
were on brief for appellant.
<span CLASS="page_no" data-cite="678 f 3d 34" data-cite-type="PrimaryFederalReporter" data-cite-pageno="34" data-primary-citation="678 F.3d 30">[*34]</span> </p></div>
<div id="para2" printdualcolumn="true"><p>
Joseph P. Lucia, David R. Geiger, Nabeel Ahmad, Foley Hoag LLP and Hugh F.
Young, Jr., Product Liability Advisory Council, Inc., on brief for the
Product Liability Advisory Council, Inc., Amicus Curiae.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Keith M. Jensen with whom Eric N. Roberson, Jensen &amp; Associates, PLLC,
Steven M. Gordon, Christine M. Craig and Shaheen &amp; Gordon were on brief for
appellee.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Louis M. Bograd, Center for Constitutional Litigation, P.C., Andru H.
Volinsky, Chair, New Hampshire Association for Justice Amicus Committee, and
Bernstein Shur, P.C. on brief for the American Association for Justice and
the New Hampshire Association for Justice, Amici Curiae.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before BOUDIN, STAHL and THOMPSON, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
BOUDIN, Circuit Judge.

</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This products liability case arises out of severe and permanent injuries
sustained by plaintiff Karen Bartlett after taking sulindac, a generic
non-steroidal anti-inflammatory drug ("NSAID") manufactured by (among
others) defendant Mutual Pharmaceutical Company ("Mutual"). Sulindac is
known to cause, in rare instances, a hypersensitivity reaction called
Stevens-Johnson Syndrome and its more generous cousin toxic epidermal
necrolysis ("SJS/TEN"). In December 2004, Bartlett's doctor prescribed (for
her shoulder pain) sulindac under the brand-name Clinoril made by the
original provider, and her pharmacist dispensed generic sulindac.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The consequences were disastrous. Bartlett developed SJS/TEN early in
2005. TEN is diagnosed when 30 percent or more of the outer skin layer on a
patient's total body surface area has deteriorated, been burned off or
turned into an open wound. In Bartlett's case, the percentage rose to 60-65
percent of her body; she spent 70 days at Massachusetts General Hospital &mdash;
including over 50 in its burn unit. Both her suffering and permanent injury,
including permanent near-blindness, are described below in connection with
the award of damages.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bartlett brought a bevy of claims against Mutual in New Hampshire state
court, including claims for breach of warranty, fraud, and negligence, as
well as the perennial trio of products liability claims: design defect,
failure to warn, and manufacturing defect. After Mutual removed the case to
federal court on diversity <span CLASS="page_no" data-cite="2012 bl 107526 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> grounds, all but the design defect claim were
dismissed by the district court on summary judgment or voluntarily by
Bartlett. <i>Bartlett v. Mutual Pharm. Co.</i>, No. 08-cv-358, 2010 WL 3659789
(D.N.H. Sept. 14, 2010); <i>Bartlett v. Mutual Pharm. Co.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1DL64E003?jcsearch=731%20f%20supp%202d%20135&amp;summary=yes#jcite">731 F.Supp.2d 135</a>
(D.N.H.2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bartlett originally planned her evidence across a range of possible
claims, including an attack on the adequacy of the warning label and
information that accompanied Mutual's sulindac drug. It was not until after
the trial was completed that further legal developments (discussed below)
fore-closed a direct attack on the adequacy of the label; but the district
court dismissed Bartlett's warning claim because her prescribing doctor
admitted that he had not read the box label or insert. <i>Bartlett</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1DL64E003?jcsearch=731%20f%20supp%202d%20135&amp;summary=yes#jcite">731 F.Supp.2d at 146-49</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although Bartlett's experts had prepared their initial reports to cover
multiple theories advanced in the complaint, by trial the core remaining
theory of design defect was narrowed to this: that sulindac's risks
outweighed its benefits making it unreasonably dangerous to consumers,
despite the federal Food and Drug Administration ("FDA") having never
withdrawn its statutory "safe and effective" designation that the original
manufacturer had
<span CLASS="page_no" data-cite="678 f 3d 35" data-cite-type="PrimaryFederalReporter" data-cite-pageno="35" data-primary-citation="678 F.3d 30">[*35]</span> 
secured and on which Mutual was entitled to piggyback.
<i>See</i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1), <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">(d)</a> (2006); <i><cite>id</cite>.</i> <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)&amp;summary=yes#jcite">&sect; 355(j)(2)(A)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A 14-day trial occurred in late August and early September 2009, during
which Bartlett called witnesses to her suffering and her treatment,
including two important experts: a burn surgeon and &mdash; more critical to
design defect &mdash; a pharmacologist/toxicologist. The latter expert in
particular sought to show from incident reports made to the FDA and other
information that sulindac had a worse record of causing SJS/TEN than other
available drugs, and a safety profile similar to other drugs deemed
dangerous enough to have been withdrawn from the market &mdash; such as
valdecoxib, another NSAID sold under the brand name Bextra, which was
withdrawn in 2005.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual had designated its own expert in the same field as well as other
witnesses but ultimately chose to put on no affirmative case of its own,
although it cross-examined Bartlett's experts vigorously and offered
substantial legal arguments to the judge as to why it should not be found
liable. After several days of deliberation, the jury found for Bartlett and
awarded $21.06 million in compensatory damages. The district court denied
Mutual's motion for judgment as a matter of law, Fed. R.Civ.P. <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X144L3U003?jcsearch=Fed.%20R.%20Civ.%20P.%2050(b)&amp;summary=yes#jcite">50</a>(b), and
motion for a new trial, Fed.R.Civ.P. <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X144L4I003?jcsearch=Fed.%20R.%20Civ.%20P.%2059&amp;summary=yes#jcite">59</a>. <i>Bartlett v. Mutual Pharm. Co.</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20f%20supp%202d%20220&amp;summary=yes#jcite">760 F.Supp.2d 220</a> (D.N.H. 2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual now appeals, arguing that the district court misunderstood New
Hampshire law on design defect claims; that such claims as to generic drugs
are preempted under federal law; that causation was not proved; that
Bartlett's expert evidence was inadmissible on multiple grounds; that
instructions as to label warnings were inaccurate; that misconduct by
Bartlett's counsel required a new trial; and that damages were excessive and
required a new trial. The standard of review depends upon the issue, the
first two raising strictly issues of law that we review <i>de novo. U.S. ex</i>
<i>rel. Loughren <span CLASS="page_no" data-cite="2012 bl 107526 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> v. Unum Grp.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1DOSSS003?jcsearch=613%20f%203d%20300&amp;summary=yes#jcite">613 F.3d 300</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1DOSSS003?jcsearch=613%20f%203d%20300&amp;summary=yes#jcite">307-08</a> (1st Cir.2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Design Defect.</i> Although courts "traditionally have refused to review the
reasonableness of the designs of prescription drugs," <i>Restatement (Third) of</i>
<i>Torts: Products Liability</i> <cite>&sect; 6</cite>, cmt. <i>f</i>, at 156 (1998), this court reads New
Hampshire law now to permit such review, <i>Brochu v. Ortho Pharm. Corp.</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X2VAJH?jcsearch=642%20f%202d%20652&amp;summary=yes#jcite">642 F.2d 652</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X2VAJH?jcsearch=642%20f%202d%20652&amp;summary=yes#jcite">655</a> (1st Cir.1981). <i>Brochu</i> is consistent with the New
Hampshire Supreme Court's adoption of <i>Restatement (Second) of Torts</i> &sect; 402A
(1965), <i>see Buttrick v. Lessard</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3QGRO?jcsearch=110%20new%20hampshire%2036&amp;summary=yes#jcite">110 N.H. 36</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3QGRO?jcsearch=260%20atlantic%202d%20111&amp;summary=yes#jcite">260 A.2d 111</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3QGRO?jcsearch=260%20atlantic%202d%20111&amp;summary=yes#jcite">113</a> (1969),
which "imposes liability for selling `any product in a defective condition
unreasonably dangerous to the user or consumer' when the product causes
injury to the user or consumer."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  However, Mutual interprets <i>Buckingham v. R.J. Reynolds Tobacco Co.</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3QTF4?jcsearch=142%20new%20hampshire%20822&amp;summary=yes#jcite">142 N.H. 822</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3QTF4?jcsearch=713%20atlantic%202d%20381&amp;summary=yes#jcite">713 A.2d 381</a> (1998), to require not merely unreasonable
dangerousness but also proof that there exists an alternative, safer design
for the product (like a new guard on a motorized table saw), <i>see </i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3QTF4?jcsearch=142%20N.H.%20822&amp;summary=yes#jcite">id. at 384</a>.
The claim in <i>Brochu</i> could satisfy such a test, because the drug at issue
there contained a mix of progestogen and estrogen, and its unreasonable
dangerousness could be attributed to the design-flaw of an unnecessarily
high proportion of estrogen.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  By contrast, Mutual says that Bartlett failed to allege and prove that
sulindac could be made in a different and safer form, and this almost
certainly has to be true: sulindac is a one-molecule drug; and the
variations in sulindac as sold consist of
<span CLASS="page_no" data-cite="678 f 3d 36" data-cite-type="PrimaryFederalReporter" data-cite-pageno="36" data-primary-citation="678 F.3d 30">[*36]</span> 
inactive ingredients that ordinarily do not have significant pharmacological
effects. But <i>Buckingham</i> does not clearly say that a safer alternative is a
necessary element of design defect over and above an unreasonably dangerous
product, and a subsequent decision disavows any such requirement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Vautour v. Body Masters Sports Indus., Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XGGU6T?jcsearch=147%20new%20hampshire%20150&amp;summary=yes#jcite">147 N.H. 150</a>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XGGU6T?jcsearch=784%20atlantic%202d%201178&amp;summary=yes#jcite">784 A.2d 1178</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XGGU6T?jcsearch=784%20atlantic%202d%201178&amp;summary=yes#jcite">1183</a> (2001), which followed after <i>Buckingham</i>, the New
Hampshire Supreme Court held that proof of a safer alternative design
"should be neither a controlling factor nor an essential element that must
be proved in every [design defect] case." Rather, it said that "a product is
defective as designed `if the magnitude of the danger outweighs the utility
of the product.'" <i></i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XGGU6T?jcsearch=784%20A.2d%201178&amp;summary=yes#jcite">Id. at 1182</a> (quoting Keeton et al., <i>Prosser and Keeton on</i>
<i>the Law of Torts</i> <cite>&sect; 99</cite>, at 699 (5th ed.1984)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Buckingham</i> involved a design defect claim against cigarette manufacturers,
and the court dismissed the claim on the ground that cigarettes are
inherently dangerous <i>and</i> commonly known to be so. <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3QTF4?jcsearch=713%20atlantic%202d%20381&amp;summary=yes#jcite">713 A.2d at 384</a>; <i>see also</i>
<i>Restatement (Second) of Torts</i> <cite>&sect; 402A</cite>, cmt. <i>i</i> (danger "beyond that which
would be contemplated by the ordinary consumer"). But an ordinary consumer
would hardly know without further warning that sulindac or any other
ordinary analgesic carries a risk of the kind of ill effects and suffering
that Bartlett encountered.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, the district court properly allowed Bartlett to show that
sulindac was in a "defective condition" by showing that it was "unreasonably
dangerous" due to its propensity to cause SJS/TEN &mdash; a harrowing
hypersensitivity reaction characterized by necrosis of the skin and mucous
membranes, and often causing blindness or death. Although Mutual could <span CLASS="page_no" data-cite="2012 bl 107526 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> still
have avoided liability by proving that sulindac was unavoidably unsafe but
was highly useful and had an adequate safety warning, <i>Bartlett</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1DL64E003?jcsearch=731%20f%20supp%202d%20135&amp;summary=yes#jcite">731 F.Supp.2d at 150-51</a>; <i>Restatement (Second) Torts</i> <cite>&sect; 402A</cite>, cmt. <i>k</i>, Mutual
abandoned that defense on the eve of trial.<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual restates its no-defect argument as an issue of causation; but given
the overwhelming evidence that sulindac triggered Bartlett's reaction, "but
for" cause is plainly established, <i>Bartlett</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20F.%20Supp.%202d%20220&amp;summary=yes#jcite">760 F.Supp.2d at 246</a>. Mutual's
position that "Bartlett could not present evidence that a nonexistent defect
in the sulindac proximately caused her injury," merely restates the argument
about New Hampshire law that we have just rejected.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Preemption.</i> The most far-reaching of Mutual's objections is that
Bartlett's design defect claim is preempted by the Federal Food, Drug, and
Cosmetic Act, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XEI5LU003?jcsearch=21%20usc%20301&amp;summary=yes#jcite">21 U.S.C. &sect; 301</a><i>et seq.</i> ("FDCA"), and &mdash; in particular &mdash; by the
Drug Price Competition and Patent Term Restoration Act of 1984, Pub.L. No.
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/1?citation=USACTS%2098-417&amp;summary=yes#jcite">98-417</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/1?citation=98%20stat%201585&amp;summary=yes#jcite">98 Stat. 1585</a> (1984) (codified at <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A))
("Hatch-Waxman Amendments"), and its regulations. Whether and to what extent
the FDCA preempts design defect claims against generic drug manufacturers is
a question of exceptional importance that the Supreme Court has yet to
decide.
<span CLASS="page_no" data-cite="678 f 3d 37" data-cite-type="PrimaryFederalReporter" data-cite-pageno="37" data-primary-citation="678 F.3d 30">[*37]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because prescription drugs and their warnings are closely regulated by the
FDA, Congress might explicitly, or the Supreme Court by implication, have
preempted state design defect or inadequate warning claims that allow state
juries to second-guess the FDA's seal of approval. But the statute contains
no general preemption provision, and in <i>Wyeth v. Levine</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. 555</a>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=173%20l%20ed%202d%2051&amp;summary=yes#jcite">173 L.Ed.2d 51</a> (2009), the Supreme Court rejected implied
preemption, saying that "Congress did not intend FDA oversight to be the
exclusive means of ensuring drug safety and effectiveness," <i></i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=555%20U.S.%20555&amp;summary=yes#jcite">id. at 575</a>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>, and that state law serves as a "complementary form of drug
regulation," <i></i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=555%20U.S.%20555&amp;summary=yes#jcite">id. at 578</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although <i>Wyeth's</i> holding was technically limited to failure-to-warn
claims,<a HREF="#fn200" name="fnref_fn200">[fn2]</a> its logic applies to design defect claims as well. <i>See Wyeth</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 574</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a> (state tort suits "motivat[e] manufacturers
to produce safe and effective drugs <i>and</i> to give adequate warnings")
(emphasis added); <i>cf. Wimbush v. Wyeth</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1E2PIM003?jcsearch=619%20f%203d%20632&amp;summary=yes#jcite">619 F.3d 632</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1E2PIM003?jcsearch=619%20f%203d%20632&amp;summary=yes#jcite">645</a> &amp; n. 7 (6th
Cir.2010) (negligent marketing claim not preempted). The lower courts agree
that the FDCA does not preempt state tort suits against drug manufacturers.
<i>See Riegel v. Medtronic, Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. 312</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">340</a> n. 11, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18HPKU003?jcsearch=343&amp;summary=yes#jcite">343</a> n. 16,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18HPKU003?jcsearch=169%20l%20ed%202d%20892&amp;summary=yes#jcite">169 L.Ed.2d 892</a> (2008) (Ginsburg, J., dissenting) (collecting
cases).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  However, in <i>PLIVA Inc. v. Mensing</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=131%20S.Ct.%202567&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=131%20supreme%20court%202567&amp;summary=yes#jcite">131 S.Ct. 2567</a>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=180%20l%20ed%202d%20580&amp;summary=yes#jcite">180 L.Ed.2d 580</a> (2011), the Court carved out an exception to <i>Wyeth</i>, finding
that the FDCA preempts <i>failure-to-warn</i> claims against <i>generic</i> drug
manufacturers. Generic drug manufacturers, unlike brand-name manufacturers,
cannot unilaterally change their labels, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XMJ53K003?jcsearch=21%20C.F.R.%20%20314.94(a)(8)(iv)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.94</a>(a)(8)(iv)
(2011), and thus cannot comply with both federal labeling standards and
state law requirements deviating from those standards.
<i>PLIVA</i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=131%20supreme%20court%202567&amp;summary=yes#jcite">131 S.Ct. at 2578</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There is no doubt that Congress wanted to reduce medical costs by spurring
generic copycat drugs, and accordingly generic manufacturers do not, after
patent protection lapses, need separate FDA approval to manufacture approved
drugs or employ their approved labeling. <i>See PLIVA</i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=131%20supreme%20court%202567&amp;summary=yes#jcite">131 S.Ct. at 2574</a>, <i></i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=id.%20at%202582&amp;summary=yes#jcite">id. at
2582</a>; <i>see also</i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A). But, as the generic maker <span CLASS="page_no" data-cite="2012 bl 107526 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> cannot
alter the labeling, <i>PLIVA</i> held that Congress cannot have wanted the generic
to pay damages under state law for a label that the FDA required.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual argues with some force that the generic maker also cannot alter the
composition of the drug and so <i>PLIVA</i>'s policy of encouraging generics by
preempting state tort claims should extend to design defect as well as
claims based on inadequate warning. But although Mutual cannot legally make
sulindac in another composition (nor is it apparent how it could alter a
one-molecule drug anyway), it certainly can choose not to make the drug at
all; and the FDCA might permit states to tell Mutual it ought not be doing
so if risk-benefit analysis weights against the drug, despite what the
Supreme Court made of similar arguments in the labeling context.
<span CLASS="page_no" data-cite="678 f 3d 38" data-cite-type="PrimaryFederalReporter" data-cite-pageno="38" data-primary-citation="678 F.3d 30">[*38]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This is second-guessing the FDA (unless new information emerged known to
the maker but not the FDA), but <i>Wyeth</i> resolved the conflict against general
preemption. And, not only has the Supreme Court not yet said it would extend
<i>PLIVA</i>'s exception to design defect claims, but &mdash; while the generic maker has
no choice as to label &mdash; the decision to make the drug and market it in New
Hampshire is wholly its own. Thus, Bartlett having lost her warning claim by
the mere chance of her drug store's selection of a generic, the Supreme
Court might be less ready to deprive Bartlett of her remaining avenue of
relief.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  True, such arguments can be turned on their head.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> To refuse
preemption here is consistent with <i>Wyeth</i> but in tension not with the holding
but with part of <i>PLIVA</i>'s rationale; a generic maker can avoid defective
warning lawsuits as well as design defect lawsuits by not making the drug;
and while <i>PLIVA</i> is itself a limited departure from a general rule of <i>Wyeth</i>,
an extension of <i>PLIVA</i> to design defect claims would comprise a general rule
for generics (although not one <i>PLIVA</i> expressly adopted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On balance, we conclude that the Court adopted a general no-preemption
rule in <i>Wyeth</i> and that it is up to the Supreme Court to decide whether
<i>PLIVA</i>'s exception is to be enlarged to include design defect claims. <i>Cf.</i>
<i>Khan v. State Oil Co.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3POR5?jcsearch=93%20f%203d%201358&amp;summary=yes#jcite">93 F.3d 1358</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3POR5?jcsearch=93%20f%203d%201358&amp;summary=yes#jcite">1362-64</a> (7th Cir.1996), <i>vacated and</i>
<i>remanded</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X5CCVF?jcsearch=522%20us%203&amp;summary=yes#jcite">522 U.S. 3</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X5CCVF?jcsearch=118%20supreme%20court%20275&amp;summary=yes#jcite">118 S.Ct. 275</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X5CCVF?jcsearch=139%20l%20ed%202d%20199&amp;summary=yes#jcite">139 L.Ed.2d 199</a> (1997). Given the
widespread use of generic drugs and the developing split in the lower
courts, <i>see</i> note 3, above, this issue needs a decisive answer from the only
court that can supply it.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Expert, Testimony.</i> Next in the crosshairs are Bartlett's experts &mdash;
pharmacologist/toxicologist Randall Tackett and burn surgeon Roger
Salisbury. Mutual argues they were not qualified to offer their opinions,
and that the opinions were either unreliable or undisclosed in their expert
reports. The governing law is set forth in the Federal Rules of Evidence and
Civil Procedure,<a HREF="#fn400" name="fnref_fn400">[fn4]</a> and <i>Daubert v. Merrell Dow Pharms., Inc.</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X2N776?jcsearch=509%20us%20579&amp;summary=yes#jcite">509 U.S. 579</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X2N776?jcsearch=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X2N776?jcsearch=125%20l%20ed%202d%20469&amp;summary=yes#jcite">125 L.Ed.2d 469</a> (1993), which makes the judge
the gatekeeper to assure that purported scientific evidence has legitimate
basis. We review for abuse of discretion, <i>Milward v. Acuity Specialty Prods.</i>
<i>Grp.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1F5DQ8003?jcsearch=639%20f%203d%2011&amp;summary=yes#jcite">639 F.3d 11</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1F5DQ8003?jcsearch=639%20f%203d%2011&amp;summary=yes#jcite">13</a> (1st Cir.2011), <i>cert. denied</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=131%20S.Ct.%202567&amp;summary=yes#jcite">___ U.S. ___</a>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=132%20supreme%20court%201002&amp;summary=yes#jcite">132 S.Ct. 1002</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=181%20l%20ed%202d%20734&amp;summary=yes#jcite">181 L.Ed.2d 734</a> (2012), and find none here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Tackett and Salisbury offered a variety of opinions, the most relevant
here <span CLASS="page_no" data-cite="2012 bl 107526 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> relating to sulindac's risks and benefits. The district court found
unreliable any explicit opinion that sulindac has a higher risk of causing
SJS/TEN than other NSAIDs &mdash; what it called an opinion about "relative risk."
But otherwise, the district court allowed Bartlett's experts:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      -to opine that sulindac's overall risk/benefit profile was
    unfavorable for marketing
<span CLASS="page_no" data-cite="678 f 3d 39" data-cite-type="PrimaryFederalReporter" data-cite-pageno="39" data-primary-citation="678 F.3d 30">[*39]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      -to opine that aspirin and acetaminophen, which have no known
    connection to SJS/TEN, are safer alternatives to sulindac
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      -to discuss voluntary "adverse event reports" (AERs) from
    prescribing doctors to the FDA, and the limitations of such data
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      -to opine &mdash; based on the number of AERs and an estimated number of
    sulindac prescriptions &mdash; on the "reporting rate" of SJS/TEN, and to
    compare drugs' reporting rates
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      -to offer various opinions about the inadequacy of sulindac's
    warning to counteract its dangerousness
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      -and to opine that the FDA lacks the resources to ensure that all
    marketed drugs are safe and effective.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual argues that the two experts were not qualified, noting that neither
witness ever prescribed an NSAID, and Tackett is not authorized to prescribe
any drugs. But Salisbury is a burn surgeon with over 35 years' experience
who treated more than 400 patients with SJS/TEN. Tackett is a pharmacologist
and pharmacology professor with over 30 years' experience. Both had some
experience with the FDA through their 2005 Citizen's Petition requesting an
SJS/TEN risk assessment and labeling change for ibuprofen. And their reports
demonstrate substantial familiarity with the relevant medical literature.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alternatively, Mutual argues that the opinions lack scientific basis and
were inadmissibly unreliable, focusing on their use of AERs, voluntary
reports from medical professionals and consumers to the FDA regarding
patients' adverse reactions to pharmaceuticals. The FDA collects this
information; and relevant data for sulindac included 89 reports of SJS/TEN
from 1980 to 1997, increasing to 134 by 2004; 39 cases of death; and one of
the highest SJS/TEN reporting rates among NSAIDs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual says there are no quality controls on spontaneous reports; that
various biases may increase reporting, including increased reporting
following introduction of a new warning (a phenomenon called the "Weber
effect"); and the difficulty of determining the number of total
prescriptions ("denominator data") to determine a reporting rate. The FDA
itself warns that "[a]ccumulated case reports cannot be used to calculate
incidence or estimates of drug risk." Mutual also argues there is no
accepted methodology for comparing drugs based on adverse event data.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  But proof that a significant number of adverse reports exists is part of
the calculus and surely relevant input for a witness who is prepared to
opine on the risk-benefit ratio based on a range of considerations. Mutual's
own designated expert, Robert Stern, relied on adverse event data and
comparative reporting rates in a peer-reviewed publication designed to
quantify the risk of SJS/TEN associated with the use <span CLASS="page_no" data-cite="2012 bl 107526 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> of NSAIDs ("Mockenhaupt
2003"). And the FDA itself considered the SJS/TEN reporting rate of Bextra &mdash;
another NSAID &mdash; in recommending its withdrawal, and published a study
comparing SJS/TEN reporting rates among certain NSAIDs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As for biases that might distort the level of reporting, these are usually
matters to be developed on cross-examination and go to the weight of the
evidence unless the biases are so overwhelming as to make the data useless.
And, as icing on the cake, at least one well-recognized limitation of
adverse event data &mdash; <i>under</i> reporting &mdash; actually works in Bartlett's favor.
<i>Bartlett</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20F.%20Supp.%202d%20220&amp;summary=yes#jcite">760 F.Supp.2d at 234</a>. Controlled studies would likely be superior
but apparently none were available to quantify sulindac's
<span CLASS="page_no" data-cite="678 f 3d 40" data-cite-type="PrimaryFederalReporter" data-cite-pageno="40" data-primary-citation="678 F.3d 30">[*40]</span> 
incidence of causing SJS/TEN. <i></i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20F.%20Supp.%202d%20220&amp;summary=yes#jcite">Id. at 237</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual is correct that in some cases courts found AERs and similar case
reports insufficient to establish that a drug caused a certain adverse
event, but these involved adverse events with innumerable possible causes
(e.g. suicidal behavior, strokes, or birth defects).<a HREF="#fn500" name="fnref_fn500">[fn5]</a> Here, sulindac is
a recognized cause of SJS/TEN and the evidence is that it caused Bartlett's
SJS/TEN. <i>Cf. Thomas v. Hoffman-LaRoche, Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3568O?jcsearch=949%20f%202d%20806&amp;summary=yes#jcite">949 F.2d 806</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3568O?jcsearch=949%20f%202d%20806&amp;summary=yes#jcite">815</a> n. 38 (5th
Cir.), <i>cert. denied</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X5JHNH?jcsearch=504%20us%20956&amp;summary=yes#jcite">504 U.S. 956</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X5JHNH?jcsearch=112%20supreme%20court%202304&amp;summary=yes#jcite">112 S.Ct. 2304</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X5JHNH?jcsearch=119%20l%20ed%202d%20226&amp;summary=yes#jcite">119 L.Ed.2d 226</a> (1992)
(10 seizure reports of dubious connection to the drug at issue).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Further, the district court excluded opinions based on what Tackett
admitted to be unreliable &mdash; namely, a direct comparison of sulindac's risk
of SJS/TEN to other NSAIDs (including Bextra). The district court also
admonished counsel not to confuse "reporting rates" with "actual incidence
rates," and instructed the jury that, while it had heard evidence about
sulindac's SJS/TEN reporting rate, it had not heard evidence about the
actual rate at which sulindac causes SJS/TEN. But it was at least a
sufficient danger that sulindac's labeling, whether adequately or not,
warned doctors about it.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, Mutual argues that Bartlett's experts failed to account for various
shortcomings in adverse event data &mdash; for example, that they failed to
consider whether the "Weber effect" increased sulindac's adverse event
reporting; that sulindac's reporting rate in certain years may have been
inflated because prescription data had to be approximated; and that
Tackett's initial report count was inflated by duplicate reports and reports
in which sulindac was not the cause of the adverse effect (Tackett later
supplied corrected data).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  But these objections were raised mid-trial although apparently known to
Mutual much earlier, and Mutual was free to &mdash; and did &mdash; highlight the flaws
on cross-examination. Mutual was also free to develop evidence to show
lesser benefits or greater dangers from alternative NSAIDs or similar drugs
like acetaminophen. Mutual finally objects that the experts did not testify
to the ultimate issue of "unreasonable dangerousness," but that was at the
district court's order and was meant to work to Mutual's benefit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Mutual argues that the opinions, bases and supporting materials
used by Bartlett's experts at trial were not adequately disclosed in the
pre-trial disclosures for expert testimony. <span CLASS="page_no" data-cite="2012 bl 107526 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> The original expert reports
focused on some issues &mdash; labeling and marketing in particular &mdash; that were
downplayed or dropped as the case was narrowed; but, as the district court
declared, "the reports were filled with opinions about sulindac's risks and
benefits," the weighing of which determines unreasonable dangerousness and,
ultimately, design defect. <i>Bartlett</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20F.%20Supp.%202d%20220&amp;summary=yes#jcite">760 F.Supp.2d at 233</a>. So Mutual was
hardly ambushed by the main thrust of the experts' testimony.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  But Mutual does claim that some important underpinnings were not
adequately disclosed in Tackett's expert report which, together with expert
depositions, is what allows the other side to prepare its own experts and
effectively cross-examine at trial. <i>Metavante Corp. v. Emigrant Sav. Bank</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1E44TE003?jcsearch=619%20f%203d%20748&amp;summary=yes#jcite">619 F.3d 748</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1E44TE003?jcsearch=619%20f%203d%20748&amp;summary=yes#jcite">762</a> (7th Cir.2010), <i>cert. denied</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=131%20S.Ct.%202567&amp;summary=yes#jcite">___ U.S. ___</a>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=131%20supreme%20court%201784&amp;summary=yes#jcite">131 S.Ct. 1784</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1FK52G003?jcsearch=179%20l%20ed%202d%20653&amp;summary=yes#jcite">179 L.Ed.2d 653</a> (2011). <span CLASS="page_no" data-cite="678 f 3d 41" data-cite-type="PrimaryFederalReporter" data-cite-pageno="41" data-primary-citation="678 F.3d 30">[*41]</span> This

kind of policing is primarily a matter for the district judge, <i>Gay v.</i>
<i>Stonebridge Life Ins. Co.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1GKO9S003?jcsearch=660%20f%203d%2058&amp;summary=yes#jcite">660 F.3d 58</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1GKO9S003?jcsearch=660%20f%203d%2058&amp;summary=yes#jcite">64</a> (1st Cir.2011), but in extreme
cases, appellate review is a backstop, <i>see Licciardi v. TIG Ins. Grp.</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X47UOK?jcsearch=140%20f%203d%20357&amp;summary=yes#jcite">140 F.3d 357</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X47UOK?jcsearch=140%20f%203d%20357&amp;summary=yes#jcite">363-64</a> (1st Cir.1998).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In this case, Mutual lays special stress on two documents. One concerns a
2005 FDA analysis of NSAID risks (the "Bextra Memo") connected to the
ultimate withdrawal of Bextra, a different NSAID, because of undue SJS/TEN
risk. Contrary to Mutual's assertion, the Bextra Memo was cited in Tackett's
report not merely for the proposition that the FDA had approved NSAID
labeling changes; it also was cited to draw comparisons between Bextra and
sulindac, and Mutual cannot properly claim to have been ambushed by this
use.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  More dangerous to Mutual were data relied on by Tackett from a draft
report on NSAID SJS/TEN risk, prepared by Robert Stern (who, again, was
Mutual's designated expert) for the drug company Pharmacia (the "Pharmacia
Report"), in forming his opinion about sulindac's high reporting rate of
SJS/TEN. The Pharmacia Report has a storied history in this litigation &mdash;
with Bartlett faulting Stern for failing to disclose the report during
discovery, and the district court ordering supplemental deposition of Stern
about it, only to discover that Tackett knew about the report all along.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Tackett at least cited the eventually-published version ("Mockenhaupt
2003") in support of statements in his expert report that "Sulindac had
significantly and substantially higher rates of reported SJS/TEN reactions
relative to the office visits compared to other NSAIDs," that "Sulindac
ranked in the top 5 of all drugs to cause SJS and TEN between 1980-1997,"
and "[c]ompared to other NSAIDs Sulindac had a higher reporting rate of SJS
and TEN." Although the Pharmacia Report added that sulindac may have had the
highest SJS/TEN reporting rate among NSAIDs from 1980 to 1997, neither the
report nor Tackett's opinion about sulindac's high SJS/TEN reporting rate
were a surprise to Mutual by the time of trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Labeling Instructions.</i> Mutual next faults the district court for telling
the jury it could "consider the FDA's requirements for drug labels" in
determining whether sulindac's warning mitigated its unreasonable
dangerousness, and for failing to instruct the jury that Mutual could not
legally change <span CLASS="page_no" data-cite="2012 bl 107526 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> sulindac's label. Mutual argues that the jury must have
inferred, incorrectly, that it could consider whether Mutual should have
improved the warnings. As already explained, under current law the original
maker, but not the generic provider, can alter the label.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  But the label was relevant to the design defect claim since, although
unalterable by Mutual, its arguable inadequacies put limits on the extent to
which its dangerousness was offset by adequate warnings; so the lack of a
clearer warning made the product itself more dangerous under the
risk-benefit test prescribed by <i>Vautour.</i> The district court's instructions,
in a section covering "The warning" did make clear that this was the
relevance of the label.<a HREF="#fn600" name="fnref_fn600">[fn6]</a> If Mutual wanted a further caution
<span CLASS="page_no" data-cite="678 f 3d 42" data-cite-type="PrimaryFederalReporter" data-cite-pageno="42" data-primary-citation="678 F.3d 30">[*42]</span> 
in the instructions, it should have sought it.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of course, at the time of the trial, <i>PLIVA</i> had not yet been decided, so
such a caution might not have been at the fore-front of Mutual's thoughts.
But the legal argument for such a caution was available to Mutual without
<i>PLIVA, cf.</i> note 2; indeed, Mutual made this very argument in seeking a new
trial before <i>PLIVA</i> was decided. Mutual failed to seek such an instruction
before the jury retired; and the instructions given were not plain error.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Counsel's Conduct.</i> In its motion for a new trial, Mutual argued that the
conduct of plaintiffs counsel was improper in various respects and that a
new trial was justified on this count alone. In a post-trial motion of this
sort, our review is for abuse of discretion; and where the charges involve
judgments about degrees of impropriety, prejudice and cumulative effect, the
trial judge has a special advantage over a reviewing court.
<i>Hatfield-Bermudez v. Aldanondo-Rivera</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X17EO18003?jcsearch=496%20f%203d%2051&amp;summary=yes#jcite">496 F.3d 51</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X17EO18003?jcsearch=496%20f%203d%2051&amp;summary=yes#jcite">64</a> (1st Cir.2007).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of the many charges, several relating to alleged non-disclosures in the
expert reports have already been answered; others are fairly trivial (a
rhetorical claim that sulindac "stole" Bartlett's freedom) or had no
conceivable impact (a sequestration order violation where Bartlett's husband
observed his sister-in-law testify but in the end did not himself appear as
a witness). We pass over such issues and focus on those that are potentially
more serious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, in voir dire Bartlett's counsel asked the jury to consider whether
it could award "$20 million or more in damages"; but Bartlett's counsel had
expressed their intent to mention specific damages figures, and Mutual did
not seek to prevent the question in advance. After Mutual objected at voir
dire, Bartlett's counsel were prohibited from mentioning total dollar
figures again until closing, and the jury was told that any amount mentioned
by counsel was "not evidence in this case."<a HREF="#fn700" name="fnref_fn700">[fn7]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, counsel also &mdash; despite an order prohibiting discussion of Mutual's
financial condition, <i>Bartlett v. Mutual Pharm. Co.</i>, No. 08-cv-358,
[<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1GCBTGU0000N?jcsearch=2010%20BL%20378014&amp;summary=yes#jcite">2010 BL 378014</a>], 2010 WL 3092649, at *8 (Aug. 2, 2010) &mdash; displayed to the jury a silent
deposition clip whose captioning indicated Mutual's $480 million sales
figure from 2007, before that clip skipped ahead to the next admissible
question-and-answer. The parties vigorously dispute whether this was merely
accidental, <span CLASS="page_no" data-cite="2012 bl 107526 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> but we accept the district court's judgment that this isolated
silent deposition clip, never again mentioned, is not basis enough for a new
trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Bartlett's counsel can be faulted in many instances for their
manner of offering evidence. Counsel frequently led their own witnesses,
although perhaps in some instances to avoid eliciting inadmissible
information. <i>Bartlett</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20F.%20Supp.%202d%20220&amp;summary=yes#jcite">760 F.Supp.2d at 257</a>. Counsel also mischaracterized
the record, including in closing argument. Counsel left prejudicial images
of Bartlett's injuries visible to the jury for longer than necessary. And
counsel attempted to use other demonstrative aids in a misleading manner.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court frequently reprimanded counsel, on occasion in front of
the jury. <i>Bartlett</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20F.%20Supp.%202d%20220&amp;summary=yes#jcite">760 F.Supp.2d at 253</a>. The judge was pro-active when he
noticed Bartlett's
<span CLASS="page_no" data-cite="678 f 3d 43" data-cite-type="PrimaryFederalReporter" data-cite-pageno="43" data-primary-citation="678 F.3d 30">[*43]</span> 
counsel misusing demonstrative and other visual aids, sometimes intervening
even where Mutual had not objected. And in some instances the judge gave
curative instructions to limit or erase any prejudice.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the end, weighing the effect on a verdict of various missteps by
counsel is a judgment call, and the district court in denying the motion for
a new trial gave reasoned consideration to Mutual's arguments based on
individual incidents. Given the comparative strength of Bartlett's expert
evidence, the prior instances of sulindac-SJS/TEN events, and the enormous
harm wrought in this instance, a judgment that misconduct did not cause the
verdict for Bartlett is not unreasonable.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Excessive Verdict.</i> Mutual next argues that the jury's damages award is
excessive. A new trial is warranted where the jury award is "grossly
excessive, inordinate, shocking to the conscience of the court, or so high
that it would be a denial of justice to permit it to stand." <i>Francescki v.</i>
<i>Hosp. Gen. San Carlos, Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X12NBHQ003?jcsearch=420%20f%203d%201&amp;summary=yes#jcite">420 F.3d 1</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X12NBHQ003?jcsearch=420%20f%203d%201&amp;summary=yes#jcite">5</a> (1st Cir.2005). The facts are
taken in the light most favorable to the plaintiff, but nevertheless the
figure must be in the "universe of acceptable awards." <i>Blinzler v. Marriott</i>
<i>Int'l, Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3A11P?jcsearch=81%20f%203d%201148&amp;summary=yes#jcite">81 F.3d 1148</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X3A11P?jcsearch=81%20f%203d%201148&amp;summary=yes#jcite">1162</a> (1st Cir.1996).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury awarded Bartlett $21.06 million-$4.56 million in largely
uncontested special damages ($1.25 million past medical expenses, $2,377
million for future medical expenses, and $933,000 for lost wages), and $16.5
million for pain, suffering, and loss of enjoyment of life. All but the last
figure rest on specific evidence that the jury accepted; but the last is, of
course, the largest number and the target of Mutual's attack.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mutual says that this is the largest award in New Hampshire history &mdash; and
more than twice the award against a car manufacturer, following a crash in
which a young child died and another was left permanently disabled. <i>Trull v.</i>
<i>Volkswagen of Am., Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X17O8FQNB5G0?jcsearch=320%20f%203d%201&amp;summary=yes#jcite">320 F.3d 1</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X17O8FQNB5G0?jcsearch=320%20f%203d%201&amp;summary=yes#jcite">3</a> (1st Cir.2002), <i>cert. denied</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18IBQNB5G0?jcsearch=540%20us%20938&amp;summary=yes#jcite">540 U.S. 938</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18IBQNB5G0?jcsearch=124%20supreme%20court%2074&amp;summary=yes#jcite">124 S.Ct. 74</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X18IBQNB5G0?jcsearch=157%20l%20ed%202d%20250&amp;summary=yes#jcite">157 L.Ed.2d 250</a> (2003). Arguably, the more
pertinent comparison is to the surviving child Nathaniel who, economic
damages aside, was awarded just under $4 million for pain and suffering and
other intangible elements of damage. <i></i><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X17O8FQNB5G0?jcsearch=320%20F.3d%201&amp;summary=yes#jcite">Id. at 9-10</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nathaniel suffered a skull fracture and bleeding that required an
operation to remove the fluid, and his experts opined that the head trauma
exacerbated a preexisting condition <span CLASS="page_no" data-cite="2012 bl 107526 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> so that he would have to live
indefinitely under supervised and structured conditions. <i>Trull</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X17O8FQNB5G0?jcsearch=320%20f%203d%201&amp;summary=yes#jcite">320 F.3d at 10</a>. The trauma of the crash, whatever suffering attended
recovery from the operation and intangible losses from a more constrained
life were thus valued by the jury at about a quarter of the amount awarded
to Bartlett for pain and suffering.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nevertheless, Bartlett's injuries were truly horrific. She spent almost
two months in MGH's burn unit, spent months in a medically-induced coma, and
suffered burns over nearly two-thirds of her body. Her burn surgeon
described the experience as "hell on earth." She spent a year being tube fed
and endured two major septic shock episodes. She suffered through 12 eye
surgeries and has many more ahead of her. This is a brief summary of the
suffering detailed for the jury.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition, the permanent damage is severe. Bartlett cannot eat normally
due to esophageal burns, cannot have sexual relations due to vaginal
injuries, and cannot engage in aerobic activities due to lung injuries. She
is almost blind now and faces some likelihood of complete and permanent
blindness. She cannot read or drive or work. And she is seriously disfigured
in face and body. In sum, the jury's award is not so clearly
disproportionate to the harm suffered that a court must set it aside.
<span CLASS="page_no" data-cite="678 f 3d 44" data-cite-type="PrimaryFederalReporter" data-cite-pageno="44" data-primary-citation="678 F.3d 30">[*44]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The outcome of this case, at least on this record, is not surprising or,
with respect to sulindac, patently alarming. True, that drug has a minuscule
risk of causing SJS/TEN, but sulindac is a recognized cause of SJS/TEN &mdash;
potentially a leader among NSAIDs in that respect &mdash; and the drug carries
other risks as well. And how far it has advantages over similar medicines
with less or no risk is unclear in light of the limited defense offered; at
most cross-examination suggested that sulindac may be the only approved
NSAID for certain forms of arthritis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whether or not our present regime of drug regulation and compensation for
harm is optimal is debatable; but the ability of judges to reshape the
regime in any fundamental way may be quite limited. As for the trial itself,
the district judge handled a very difficult case with skill and insight and
he deserves this court's special thanks for his thoughtful and very helpful
opinions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Affirmed.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> Although Mutual has not explained its strategy, the district court had
already rejected Bartlett's claims based on failure to warn for lack of
causation, and Mutual may have hoped to exclude entirely any evidence of the
warnings actually employed by Mutual, which had listed SJS/TEN as a
potential "adverse reaction" in its package insert without explicitly naming
SJS/TEN on the label's "warnings" section. Or, it may have thought that
Bartlett's expert testimony could be undermined without risking
cross-examination of its own expert who might have had to concede some of
the dangers posited by Bartlett.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> More specifically, <i>Wyeth</i> held that the FDCA does not preempt
failure-to-warn claims against brand-name drug manufacturers. Because the
FDA's "changes being effected" regulations,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XMJ532003?jcsearch=21%20C.F.R.%20%20314.70(c)(6)(iii)(A)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.70</a>(c)(6)(iii)(A), <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/XMJ532003?jcsearch=21%20C.F.R.%20%20314.70(c)(6)(iii)(C)&amp;summary=yes#jcite">(C)</a> (2008), permit brand-name
manufacturers to strengthen their labels unilaterally &mdash; albeit temporarily,
while application for permanent change is pending with the FDA &mdash; the Court
concluded it is possible for brand-name manufacturers to comply with both
federal labeling requirements and state tort law effectively requiring a
stronger label. <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 568</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">573</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> <i>Cf. In re Darvocet, Darvon &amp; Propoxyphene Prods. Liab. Litig.</i>, <cite>No.
2:11-md-2226</cite>, 2012 WL 718618, at *2-*3 (E.D.Ky. Mar. 5, 2012); <i>Lyman v.</i>
<i>Pfizer, Inc.</i>, No. <cite>2:09-cv-262</cite>, 2012 WL 368675, at *4 (D.Vt. Feb. 3, 2012);
<i>In re Pamidronate Prods. Liab. Liiig.</i>, Nos. <cite>09-MD-2120</cite>, <cite>10-CV-1860</cite>,
2012 WL 272889, at *3 (E.D.N.Y. Jan. 30, 2012).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Fed.R.Evid. <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X135KMG003?jcsearch=Fed.%20R.%20Evid.%20702&amp;summary=yes#jcite">702</a> (permitting qualified experts with specialized
technical knowledge to provide opinions if based on application of reliable
principles, methods, and data); Fed. R.Civ.P. <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X144L2A003?jcsearch=Fed.%20R.%20Civ.%20P.%2026(a)(2)(B)&amp;summary=yes#jcite">26</a>(a)(2)(B) (expert report
must contain "a complete statement of all opinions the witness will express
and the basis and reasons for them"); Fed.R.Civ.P. <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X144L30003?jcsearch=Fed%20R.%20Civ.%20P.%2037(c)(1)&amp;summary=yes#jcite">37</a>(c)(1) (prohibiting use
of undisclosed information).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> <i>E.g., Miller v. Pfizer, Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X4OCBF?jcsearch=196%20f%20supp%202d%201062&amp;summary=yes#jcite">196 F.Supp.2d 1062</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X4OCBF?jcsearch=196%20f%20supp%202d%201062&amp;summary=yes#jcite">1077</a> (D.Kan.2002);
<i>Siharath v. Sandoz Pharms. Corp.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X27V5K?jcsearch=131%20f%20supp%202d%201347&amp;summary=yes#jcite">131 F.Supp.2d 1347</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X27V5K?jcsearch=131%20f%20supp%202d%201347&amp;summary=yes#jcite">1361</a> (N.D.Ga.2001);
<i>Wade-Greaux v. Whitehall Labs., Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X46J7S?jcsearch=874%20f%20supp%201441&amp;summary=yes#jcite">874 F.Supp. 1441</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X46J7S?jcsearch=874%20f%20supp%201441&amp;summary=yes#jcite">1481</a> (D.Vi.1994);
<i>DeLuca v. Merrell Dow Pharms., Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X2IMQU?jcsearch=791%20f%20supp%201042&amp;summary=yes#jcite">791 F.Supp. 1042</a>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X2IMQU?jcsearch=791%20f%20supp%201042&amp;summary=yes#jcite">1050-51</a>
(D.N.J.1992).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> Mutual directs us to an allegedly contradictory statement by the
district court that "Pliability may exist if the manufacturer did not take
available and reasonable steps to lessen or eliminate the danger of even a
useful and desirable product." In context, it is clear these statements were
made regarding product design and not labeling.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> In closing, counsel suggested between $20 and $30 million for pain and
suffering alone. Although allowing counsel to do so was error under First
Circuit precedent, <i>Davis v. Browning-Ferris Indus., Inc.</i>, <a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X57BP7?jcsearch=898%20f%202d%20836&amp;summary=yes#jcite">898 F.2d 836</a>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X57BP7?jcsearch=898%20f%202d%20836&amp;summary=yes#jcite">837-38</a> (1st Cir.1990), Mutual apparently assented to counsel doing so,
provided the district court instructed the jury as described, <i>Bartlett</i>,
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1EQ5IM003?jcsearch=760%20F.%20Supp.%202d%20220&amp;summary=yes#jcite">760 F.Supp.2d at 254</a> n. 39.
</p></div>
</div>
<!--BBLS DD 1706027057155-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HKRI6003/history">Direct History (214)</a>
</div>
<div class='sidebarItemLabel bold'>
Negative Direct History
</div>
<div class='bcite'>
<div class='sidebarItemLabel'>
Judgment reversed by
</div>
<div class='citationAnalysisSideBarLabel'>
<a class="icon citation distinguished" href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1JQD4G003" title="Distinguished"></a>
<a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1JQD4G003">Mut. Pharm. Co. v. Bartlett, 133 S. Ct. 2466, 186 L. Ed. 2d 607 (2013)</a>
</div>
</div>

</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HKRI6003/analysis">Case Analysis (21)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HKRI6003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
19
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HKRI6003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
2
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceuticals</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/document/X1Q6LFARCEO2">10-02277 (1st Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Evidence</div><div class='facetItemLabel'>Torts</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/e2ce47aedc09393b1f207adc43ffc06c/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "e2ce47aedc09393b1f207adc43ffc06c";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY7b6f42&previousPageId=&previousActivityInstanceId=ENTITY3c4aff&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:46:05-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HKRI6003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY3c4aff&previousPageId=&previousActivityInstanceId=ENTITY7024e7&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:45:56-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HKRI6003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HKRI6003";
$('#page_loader').show().spin();
JUDGE_IDS=["17118134","3027822","3027842"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
